Abstract: The present disclosure generally relates to methods and formulations for treating central nervous system (CNS) disorders. The present disclosure involves intranasal delivery of at least one antioxidant compound, allowing for effective treatment of a central nervous system disorder such as traumatic brain injury or stroke.
Abstract: The present disclosure generally relates to methods and formulations for treating central nervous system (CNS) disorders. The present disclosure involves intranasal delivery of at least one antioxidant compound, allowing for effective treatment of a central nervous system disorder such as traumatic brain injury or stroke.
Abstract: A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>?Htr (1) (wherein ?Htr represents the endotherm (J/g) accompanying a transition at about 240° C.). The solid dispersion product shows an improved bioavailability.
Type:
Grant
Filed:
June 21, 2013
Date of Patent:
October 6, 2015
Assignees:
Abbvie Deutschland GmbH & Co KG, Barrier Therapeutics, Inc.
Inventors:
Gunther Berndl, Matthias Degenhardt, Markus Mägerlein, Gerrit Dispersyn
Abstract: The present invention relates to the compounds of formula (I), their preparation and use as antifungal and/or antibacterial agents. where the values for R1, R2, R3, R4, R5 and A are as defined herein.
Type:
Grant
Filed:
April 23, 2008
Date of Patent:
April 3, 2012
Assignee:
Barrier Therapeutics, Inc.
Inventors:
Marcel Borgers, Maarten van Geffen, Jannie Ausma